EUVIMEDEUVIMED entdecken
Crossref

Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer

Xinyi Guo, Hu Nie, Wenwen Zhang, Jiesheng Li, Jing Ge, Bowen Xie, Wenbo Hu, Yicheng Zhu, Na Zhong, Xinmei Zhang, Xiaohong Zhao, Xiaoshuang Wang und 8 weitere

Cancer Cell · 2025-02 · 43 (2) · 248-268.e9

DOI: 10.1016/j.ccell.2025.01.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2025-02. Verfasst von Xinyi Guo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine - Affiliated Renji Hospital, …. Hauptthemen laut MEDLINE: Quinolines, Phenylurea Compounds, T-Lymphocytes, Regulatory, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 126 Literaturangaben. Gefördert von: Chinese Academy of Meteorological Sciences, Shenzhen Science and Technology Innovation Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combination of anti-PD-1 with lenvatinib showed clinical efficacy in multiple cancers, yet the underlying immunological mechanisms are unclear. Here, we compared T cells in hepatocellular carcinoma (HCC) patients before and after combination treatment using single-cell transcriptomics and T cell receptor (scTCR) clonotype analyses. We found that tumor-infiltrating GZMK+ CD8+ effector/effector memory T (Teff/Tem) cells, showing a favorable response to combination therapy, comprise progenitor exhausted T (Tpex) cells and also unappreciated circulating Tem (cTem) cells enriched with hepatitis B virus (HBV) specificity. Further integrated analyses revealed that cTem cells are specifically associated with responsiveness to the combination therapy, whereas Tpex cells contribute to responses in both combination therapy and anti-PD-1 monotherapy. Notably, an underexplored KIR+ CD8+ T cell subset in the tumor and FOXP3+ CD4+ regulatory T cells are specifically enriched in non-responders after the combination therapy. Our study thus elucidated T cell subsets associated with clinical benefits and resistance in cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesPhenylurea CompoundsT-Lymphocytes, RegulatoryCarcinoma, HepatocellularLiver NeoplasmsProgrammed Cell Death 1 ReceptorT-Lymphocytes, CytotoxicImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleCD8-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

CD8(+)KIR(+)T cellcirculating effector or effector memory T cellhepatitis B virusimmune checkpoint blockadesingle-cell RNA sequencing

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Shanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine - Affiliated Renji Hospital, Shanghai 200127, China; Institute for Immunology, Tsinghua-Peking Cent…
  • Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, Guangdong 518132, China; State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, School of Chemical Biology and Biote…
  • Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital / Key Laboratory of Digital Hepatobiliary Surgery, PLA / Institute of Hepatobiliary Surgery of Chinese PLA, Beijing 100953, China.
  • Shanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine - Affiliated Renji Hospital, Shanghai 200127, China.
  • Institute for Immunology, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing 100084, China.
  • Shenzhen Peacock Biotechnology Co., Ltd, Shenzhen, Guangdong 518112, China.

Förderung

  • Chinese Academy of Meteorological Sciences
  • Shenzhen Science and Technology Innovation Program
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Innovative Research Team of High-level Local University in Shanghai

Zitieren

APA

Guo, X., Nie, H., Zhang, W., Li, J., Ge, J., Xie, B., Hu, W., Zhu, Y., Zhong, N., Zhang, X., Zhao, X., Wang, X., Sun, Q., Wei, K., Chen, X., Ni, L., Zhang, T., Lu, S., Zhang, L., & Dong, C. (2025). Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer Cell, 43(2), 248-268.e9. https://doi.org/10.1016/j.ccell.2025.01.001

Vancouver

Guo X, Nie H, Zhang W, Li J, Ge J, Xie B, et al. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer Cell. 2025;43(2):248-268.e9. doi:10.1016/j.ccell.2025.01.001

BibTeX
@article{Guo2025,
  author = {Guo, Xinyi and Nie, Hu and Zhang, Wenwen and Li, Jiesheng and Ge, Jing and Xie, Bowen and Hu, Wenbo and Zhu, Yicheng and Zhong, Na and Zhang, Xinmei and Zhao, Xiaohong and Wang, Xiaoshuang and Sun, Qinli and Wei, Kun and Chen, Xiaoyuan and Ni, Ling and Zhang, Ting and Lu, Shichun and Zhang, Lei and Dong, Chen},
  title = {Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {2},
  pages = {248--268.e9},
  doi = {10.1016/j.ccell.2025.01.001}
}
Kostenlos starten →